BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11359677)

  • 1. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells.
    Krüger W; Kröger N; Tögel F; Badbaran A; Renges H; Gieseking F; Gutensohn K; Jänicke F; Zander AR
    J Hematother Stem Cell Res; 2001 Apr; 10(2):303-7. PubMed ID: 11359677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone.
    Franklin WA; Glaspy J; Pflaumer SM; Jones RB; Hami L; Martinez C; Murphy JR; Shpall EJ
    Blood; 1999 Jul; 94(1):340-7. PubMed ID: 10381531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of breast cancer cell detection by immunomagnetic enrichment.
    Krüger W; Tögel F; Rössing S; Kröger N; Zander AR
    Cytotherapy; 1999; 1(2):135-9. PubMed ID: 19746590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
    Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
    Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
    Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections.
    Lazarus HM; Haynesworth SE; Gerson SL; Caplan AI
    J Hematother; 1997 Oct; 6(5):447-55. PubMed ID: 9368181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of peripheral blood stem cells mobilized with granulocyte colony-stimulating factor with or without prior standard-dose chemotherapy in patients with malignancy.
    Kobayashi N; Kasai M; Masauzi N; Ogasawara M; Kiyama Y; Naohara T; Higa T; Hashino S; Tanaka J; Imamura M
    Jpn J Clin Oncol; 1995 Dec; 25(6):250-7. PubMed ID: 8523821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation.
    Avigan D; Wu Z; Gong J; Joyce R; Levine J; Elias A; Richardson P; Milano J; Kennedy L; Anderson K; Kufe D
    Clin Cancer Res; 1999 Oct; 5(10):2735-41. PubMed ID: 10537336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum G-CSF levels in patients undergoing G-CSF/chemotherapy mobilized peripheral stem cell harvest and predictors of neutrophil and platelet recovery.
    Maharaj D; Gómez-Marín O; Lewis-Ximenez LL; Riley R; Albarracín C
    Leukemia; 1995 Oct; 9 Suppl 1():S113-7. PubMed ID: 7475301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human hematopoietic progenitor in bone marrow and peripheral blood.
    Messner HA
    Stem Cells; 1998; 16 Suppl 1():93-6. PubMed ID: 11012151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic recovery in patients who are treated with autologous stem cells transplantation taken from bone marrow after granulocyte-colony-stimulating factor stimulation.
    Gawronski K; Rzepecki P; Oborska S; Wasko-Grabowska A
    Transplant Proc; 2011 Oct; 43(8):3114-5. PubMed ID: 21996240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-colony stimulating factor primed bone marrow and granulocyte-colony stimulating factor mobilized peripheral blood stem cells are equivalent for engraftment: which to choose?
    Elfenbein GJ
    Pediatr Transplant; 2005 Dec; 9 Suppl 7():37-47. PubMed ID: 16305616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination.
    Stadtmauer EA; Tsai DE; Sickles CJ; Mick R; Luger SM; Porter DL; Mangan PA; Schuchter LM; Schuster SJ; Loh EY; Magee DA; Sachs RA; Wall ME; Moore J; Buzby GP; Zaleta E; Kamoun M; Silberstein LE
    Med Oncol; 1999 Dec; 16(4):279-88. PubMed ID: 10618691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor.
    Kohno A; Takeyama K; Narabayashi M; Okamoto R; Adachi I; Tobinai K; Shimoyama M
    Bone Marrow Transplant; 1995 Jan; 15(1):49-54. PubMed ID: 7538002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.